Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026)

Ocular Therapeutix's Retained Earnings history runs 14 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 30.41% year-over-year to -$1.2 billion in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 30.41% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 29.84% from the prior year.
• Retained Earnings declined to -$1.2 billion in Q1 2026 per OCUL's latest filing, from -$1.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$558.3 million in Q1 2022 and bottomed at -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$762.4 million (2024), against an average of -$812.4 million.
• Across the five-year window, Retained Earnings retreated 4.14% in 2022 and slumped 30.41% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$616.8 million in 2022, then retreated by 13.09% to -$697.6 million in 2023, then retreated by 27.74% to -$891.1 million in 2024, then decreased by 29.84% to -$1.2 billion in 2025, then declined by 7.66% to -$1.2 billion in 2026.
• Per Business Quant, the three latest OCUL Retained Earnings figures stand at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025).